Changes in Hong Kong stocks | Changfeng Pharmaceutical (02652) rose more than 10% in the intraday period. ICF001 covers all four major indications, and has continued to buy southbound capital recently

The Zhitong Finance App learned that Changfeng Pharmaceutical (02652) rose this morning, with an intraday high of more than 10%. As of press release, it had risen 4.25% to HK$10.80, with a turnover of HK$26.96 million.

According to news, Changfeng Pharmaceutical's self-developed long-term inhalation powder candidate ICF001 has recently obtained multiple implied clinical trial licenses, achieving full coverage of the four major indications of PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this type of long-acting inhalation prodrug to the clinical trial stage in China. It is worth mentioning that Southbound Capital has continued to make net purchases recently, and the number of shares held by Hong Kong Stock Connect increased to 24.1592 million shares on September 11, and the shareholding ratio rose to 7.45%.

Dr. Liang Wenqing, Chairman and Executive Director of the company, said earlier: “ICF001 has obtained clinical development licenses for four indications, which is an important milestone in Changfeng Pharmaceutical's transformation from a complex inhalation formulation platform to a global innovative asset. Positive clinical data on similar international drugs have proven that long-lasting inhalation prodrugs can become a next-generation treatment direction with global commercial potential.”